Richter Joshua, Saif Muhammad Wasif
Yale University School of Medicine, New Haven, CT 06536-0740, USA.
JOP. 2010 Mar 5;11(2):139-43.
Although many cancers have seen a decline in rates due to screening techniques, the lack of viable screening for pancreatic cancer yields a large number of patients presenting with locally advanced and metastatic disease. Interesting new data regarding the management of locally advanced pancreatic cancer was presented at the 2010 ASCO Gastrointestinal Cancers Symposium, January 22-24, Orlando, FL, USA. Crane et al. presented phase II data exploring induction chemotherapy followed by chemoradiotherapy with multiple agents including cetuximab, gemcitabine, oxaliplatin and capecitabine (Abstract #132). Phase II data was also presented examining the role of S-1, an oral fluoropyrimidine, in the locally advanced setting (Abstract #196). In the wake of several studies exploring the role of platinum compounds in combination with gemcitabine; Raftery et al. explored the combination of oxaliplatin and gemcitabine with concomitant radiotherapy (Abstract #220). As surgical resection still represents the only clear pathway towards cure, data was presented exploring the factors associated with patients who are converted from unresectable to resectable in the locally advanced setting (Abstract #218). The authors summarize and discuss the data from the meeting.
尽管由于筛查技术的应用，许多癌症的发病率有所下降，但胰腺癌缺乏可行的筛查方法，导致大量患者在出现局部晚期和转移性疾病时才被发现。2010年1月22日至24日在美国佛罗里达州奥兰多市举行的美国临床肿瘤学会（ASCO）胃肠道癌症研讨会上，公布了有关局部晚期胰腺癌治疗的有趣新数据。克兰等人展示了II期数据，该数据探索了诱导化疗，随后采用包括西妥昔单抗、吉西他滨、奥沙利铂和卡培他滨在内的多种药物进行放化疗（摘要#132）。还展示了II期数据，研究口服氟嘧啶S-1在局部晚期情况下的作用（摘要#196）。在多项探索铂类化合物与吉西他滨联合应用作用的研究之后，拉夫特里等人研究了奥沙利铂与吉西他滨联合并同步放疗的效果（摘要#220）。由于手术切除仍然是唯一明确的治愈途径，会上公布了有关局部晚期情况下从不可切除转为可切除的患者相关因素的数据（摘要#218）。作者总结并讨论了会议上的数据。
